

Amendments to the Specification

1) In the specification, on page 1 at line 2, please insert the following:

BACKGROUND OF THE INVENTION

Field of the Invention

2) In the specification, on page 1, at line 6, please insert the following:

Description of Related Art

3) In the specification, please replace the paragraph located at lines 7-17 on page 1, with the following replacement paragraph:

It has been known for a long time that certain ~~lipopeptides~~ lipopeptides are macrophage activators (Hoffman, P., S. Heinle, U. F. Schade, H. Loppnow, A. J. Ulmer, H. D. Flad, G. Jung, and W. Bessler, 1988, "Stimulation of human and murine adherent cells by bacterial lipoprotein and synthetic bisacyoxypropylcysteine analogues", Immunobiol. 177:158-170). Peptides or proteins which are multiply fatty acid-substituted (acyloxy-substituted) at a propylcysteine residue, and which have a physiological effect, are also known, in particular, within this class of macrophage activators.

4) In the specification, on page 3 just before line 1, please insert the following:

BRIEF SUMMARY OF THE INVENTION

5) In the specification, on page 3, at line 26, please insert the following:

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1: The concentration dependence of macrophage activation, as measured by means of nitrogen monoxide production (determined spectroscopically at OD 550 nm), on the concentration of macrophage activator, in picomol.

Fig. 2: Acceleration of wound healing in diabetic mice due to the triple administration of BPP-Cys-PEG. Triangular symbols: carrier-treated control animals; square symbols: BPP-Cys-PEG-treated animals.

Fig. 3: Humoral responses which are stimulated after inoculating with MALP-2 derivatives and BPP-Cys-PEG, as mucosal adjuvants, at a dose of 0.05 μg per animal per immunization. The mice were immunized intranasally, on days 0, 7 and 14, with β -galactosidase (50 $\mu\text{g}/\text{dose}$) mixed with the above derivatives. On day 31 after the first immunization, serum samples were withdrawn and the concentrations of the β -galactosidase-specific antibodies were determined by means of ELISA. The results are depicted as end point titers.

Fig. 4: Total β -gal-specific IgA in the lung washes from intranasally immunized mice. The standard deviations (SD) are depicted by vertical lines.

Fig. 5: Total β -gal-specific IgA in the vaginal washes from intranasally immunized mice. The standard deviations are depicted as vertical lines.

Fig. 6: β -gal-specific T cell proliferation responses of spleen cells from immunized mice. The cells were re-stimulated in vitro over 4 days with different concentrations of soluble β -gal. The results are depicted as ratios between the values (means of triple determinations) from stimulated and unstimulated samples (stimulation index).

DETAILED DESCRIPTION OF THE INVENTION

6) In the specification, please delete the following paragraphs:

Please delete the paragraph beginning at line 33 and ending at line 37 on page 7.

Please delete the five paragraphs beginning at line 1 and ending at line 31 of page 8.